Detalhe da pesquisa
1.
Allosteric SHP2 inhibition increases apoptotic dependency on BCL2 and synergizes with venetoclax in FLT3- and KIT-mutant AML.
Cell Rep Med
; 4(11): 101290, 2023 11 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-37992684
2.
The Irreversible FLT3 Inhibitor FF-10101 Is Active Against a Diversity of FLT3 Inhibitor Resistance Mechanisms.
Mol Cancer Ther
; 21(5): 844-854, 2022 05 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35395091
3.
Recurrent Mutations in Cyclin D3 Confer Clinical Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia.
Clin Cancer Res
; 27(14): 4003-4011, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34103301
4.
Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.
Blood Adv
; 4(3): 514-524, 2020 02 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32040554